

Special Issue

Antibiotics and Therapeutic Agent Prescription in COVID-19 Management

Message from the Guest Editors

During the coronavirus disease 2019 (COVID-19) pandemic, only few therapeutic options have been approved for the treatment of COVID-19 with strong evidence. The spectrum of effective therapies to treat moderate-to-severe COVID-19 forms or prevent disease progression is growing and evolving rapidly. Several trials to assess the potential effectiveness of these therapeutics in hospitalized adults and outpatients, but also in specific populations such as children and pregnant women, are ongoing. However, some physicians and doctors still prescribe inappropriate treatment in COVID-19 patients. In *Antibiotics*, we present this Special Issue in view of the health emergency and the use of therapeutic agents with high uncertainty and potential for harm in order to improve treatment recommendations during COVID-19. Keywords: COVID-19; treatment; steroids; anti-interleukin-6; antibiotics; anticoagulants; immunoglobulin; antivirals; therapies; clinical trial; prescription; recommendations

Guest Editors

Dr. Souheil Zayet

Infectious Diseases Department, Nord Franche-Comté Hospital, 90400 Trevenans, France

Dr. Timothée Klopfenstein

Infectious Diseases Department, Nord Franche-Comté Hospital, Montbéliard, France

Deadline for manuscript submissions

closed (31 December 2021)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/92944

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)